SAN DIEGO, Feb. 18, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that investors, analysts, and other interested parties can access a live webcast of its upcoming investor session ...

The NIH projected the cut will save it $4 billion during the current federal fiscal year, which ends September 30. That’s nearly half of the $9 billion that the NIH said it set aside for overhead ...

Torsional stress in chromatin plays a fundamental role in cellular functions, influencing key processes such as transcription, replication, and chromatin organization. Transcription and other ...

Illumina Inc (NASDAQ:ILMN)., a leading player in the genomic sequencing industry, finds itself at a critical juncture as it navigates a shifting competitive landscape and global economic challenges.

Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief ...

A stand-alone sequencing approach was accurate, cost effective and efficient for analyzing resistant pathogens and ...

Precision Medicine Is the Future Of Healthcare When it comes to applied hard sciences, a source of progress has been more precise measurements and tools. This is especially true in physics and ...

However, 10 companies defied a broader market optimism, mostly due to a series of stock rating downgrades from investment ...

On Monday, for the second time in as many business days, Illumina ( ILMN -4.11%) stock took it on the chin because of an analyst recommendation downgrade. The biotech's shares closed the day almost 6% ...

After the National Institutes of Health (NIH) announced late Friday that it would be following a Trump administration ...

The general mood among these heavyweight investors is divided, with 37% leaning bullish and 37% bearish. Among these notable options, 4 are puts, totaling $366,099, and 4 are calls, amounting to ...

In its earnings release, ILMN widened its net loss for the full year 2024 to $1.2 billion from the $1.16 billion registered ...